News Release Details

Heron Therapeutics to Present at the JMP Securities Life Sciences Conference

06/15/2016 |

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 15, 2016-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the JMP Securities Life Sciences ConferenceWednesday, June 22, 2016, at 2:30 p.m. ET (11:30 a.m. PT) in New York, New York.

A live webcast of this presentation and accompanying slides will be available on the Company’s website at in the Investor Resources section. A replay of the presentation will be archived on the site for 60 days.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. Heron’s goal is to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use. For more information, visit

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, those associated with: the projected sufficiency of our capital position for future periods, the review of the SUSTOL NDA by the FDA, the potential market opportunity for SUSTOL and new products generally, expected timing and acceptance of the SUSTOL commercial launch, the progress in the research and development of HTX-019, HTX-011 and our other programs, including the timing of preclinical, clinical, and manufacturing activities, safety and efficacy results from our studies, and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Source: Heron Therapeutics, Inc.

Investor Relations and Media Contact:
Heron Therapeutics, Inc.
Jennifer Capuzelo, 858-703-6063
Associate Director, Investor Relations

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.